Paclitaxel in cancer therapy

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 6, 2002, Pages 755-766

  Mekhail, Tarek M ^a   Markman, Maurie ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Chemotherapy; Paclitaxel; Taxanes; Taxol

Indexed keywords

AMIFOSTINE; ANTHRACYCLINE; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GLUTAMIC ACID; GLYCOPROTEIN; HYPERTENSIVE AGENT; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PLATINUM; PYRIDOXINE; RAZOXANE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TUBULIN; UNINDEXED DRUG; VINCA ALKALOID;

AIDS RELATED COMPLEX; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLADDER CANCER; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL DEATH; CELL DIVISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESISTANCE; DRUG STRUCTURE; DRUG TRANSPORT; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GERM CELL TUMOR; HEAD AND NECK CANCER; HUMAN; HYPERSENSITIVITY REACTION; INTERPHASE; KAPOSI SARCOMA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MICROTUBULE; MYALGIA; NEUROTOXICITY; OVARY CANCER; PROTEIN FUNCTION; PROTEIN POLYMERIZATION; PROTEIN STRUCTURE; REVIEW; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; BREAST TUMOR; DRUG ADMINISTRATION; FEMALE; HEAD AND NECK TUMOR; LUNG TUMOR; MALE; OVARY TUMOR;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0036076310     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.6.755     Document Type: Review

References (106)

1. Plant antitumour agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumour agent from Taxus brevifolia
2. Paclitaxel (taxol)
3. Le taxotere: Des aiguilles d'if a la clinique
4. The taxoids. Comparative clinical pharmacology and therapeutic potential
5. Promotion of microtubule assembly in vitro by taxol
6. Taxol stabilizes microtubules in mouse fibroblast cells
7. Taxol: A novel investigational antimicrotubule agent
8. Docetaxel
9. Microtubules
10. Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor
11. Taxol binds to polymerized tubulin in vitro
12. Taxol binds to cellular microtubules
13. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins
14. Taxol-induced polymerization of purified tubulin. Mechanism of action
15. Taxol stabilization of microtubules in vitro: Dynamics of tubulin addition and loss at opposite microtubule ends
16. Interactions of taxol, microtubule-associated proteins and guanine nucleotides in tubulin polymerization
17. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations
18. Bcl-xL is phosphorylated in malignant cells following microtubule disruption
19. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review
20. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport and cell death
21. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukaemia cells
22. Relationship between the structure of taxol and other taxanes on induction of tumour necrosis factor-alpha gene expression and cytotoxicity
23. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly
24. Mechanisms of action and resistance to tubulin-binding agents
25. Paclitaxel resistance in nonsmall-cell lung cancer associated with beta-tubulin gene mutations
26. Taxol: Mechanisms of action and resistance
27. Reversal of the multi-drug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs
28. Measurement of cremophor EL following taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multi-drug resistant phenotype
29. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death
30. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
31. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
32. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: A novel role for BAX during chemotherapy-induced cell death
33. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest
34. Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells
35. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression
36. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human preB leukaemia cells
37. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
38. Successful retreatment with taxol after major hypersensitivity reactions
39. Clinical toxicities encountered with paclitaxel (Taxol)
40. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
41. Neurotoxicity of Taxol
42. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies
43. Randomized Phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer
44. Optic nerve disturbances: A new form of paclitaxel neurotoxicity
45. Ophthalmic toxicity following paclitaxel infusion
46. Antihistamines in the treatment of taxol-induced paroxystic pain syndrome
47. Cardiac disturbances during the administration of taxol
48. A reassessment of cardiac toxicity associated with Taxol
49. Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors
50. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
51. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumour efficacy and cardiac effects in a dose-finding and sequence-finding study
52. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 h: A regimen with high activity and low cardiotoxicity in advanced breast cancer
53. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer
54. Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel
55. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
56. Risk factors for doxorubicin-induced congestive heart failure
57. Polychemotherapy for early breast cancer: An overview of the randomised trials
58. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumours responsive to tamoxifen: Results from the National Adjuvant Breast and Bowel Project B-16
59. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients
60. Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII
61. Tamoxifen and chemotherapy for lymph node-negative, oestrogen receptor-positive breast cancer
62. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer
63. Adjuvant Therapy for Breast cancer
64. D C: Do women with 4 or more involved axellary lymph nodes need Taxol or just more adjuvant chemotherapy?
65. Palliative effect of chemotherapy: Objective tumour response is associated with symptom improvement in patients with metastatic breast cancer
66. Phase III trial of doxorubicin (A) versus paclitaxel + paclitaxel (A + T) as first-line therapy for metastatic breast cancer: An intergroup trial
67. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8
68. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
69. Safety and efficacy of using a single agent or a Phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: Report of a randomized study
70. Paclitaxel in breast cancer
71. Docetaxel as single-agent therapy in metastatic breast cancer: Clinical efficacy
72. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A Phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer
73. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
74. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma
75. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study
76. Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer
77. Update of the NCCN ovarian cancer practice guidelines
78. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
79. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
80. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study
81. Advanced epithelial ovarian cancer: 1998 consensus statements
82. Results of a Southwest Oncology Group Phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer
83. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials
84. Advanced Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials
85. Carboplatin and paclitaxel in ovarian carcinoma: A Phase I study of the Gynecologic Oncology Group
86. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer
87. Randomized Phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin
88. Cisplatin/paclitaxel versus carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study group trial
89. 2 over 3 h) with cisplatin or carboplatin in previously untreated ovarian cancer: An interim analysis
90. Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer
91. Paclitaxel plus carboplatin in the treatment of ovarian cancer
92. Randomized Phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158)
93. A Phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies
94. Single agent paclitaxel in advanced squamous cell head and neck carcinoma
95. Final report of a Phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern cooperative Oncology Group trial (PA390)
96. Cisplatin-paclitaxel weekly schedule in advanced solid tumours: A Phase I study
97. Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A Phase II trial
98. Chemotherapy for relapsed head and neck cancer: Paclitaxel, cisplatin and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study
99. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck
100. Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: A Phase II study conducted by the Hellenic cooperative Oncology Group
101. Chemotherapy versus supportive care in advanced nonsmall-cell lung cancer. Results of a meta-analysis of the literature
102. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
103. Phase II study of taxol in patients with untreated advanced nonsmall-cell lung cancer
104. Summary of Phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer
105. Comparison of survival and quality of life in advanced nonsmall-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Oncology Group trial
106. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer